In our study, we first investigated the function of anti-SIRPα therapy plus immunotherapy in treating HCC in a spontaneous mouse model, which is more comprehensive to verify the synergistic effect of anti-SIRPα therapy and anti-PD-L1 therapy combination therapy. The gene discussed is SIRPA; the disease is hepatocellular carcinoma.